Pazelliptine

Pazelliptine

SCHEMBL1230910

CCN(CC)CCCNc1nccc2c(C)c3[nH]c4ccncc4c3cc12.Cl.Cl.Cl

nearest known ligand 0.72

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO

The experimentally established mechanism targets of Pazelliptine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KIT known ✓ P10721 8/20 0.72
PDGFRA known ✓ P16234 2/20 0.42
FGFR3 known ✓ P22607 2/20 0.42
GAA known ✓ P10253 2/20 0.41
NR3C1 known ✓ P04150 2/20 0.38
LCK known ✓ P06239 1/20 0.37
TOP2A known ✓ P11388 1/20 0.37
KCNH2 known ✓ Q12809 1/20 0.37
PAX8 Q06710 1/20 0.42
NQO1 P15559 1/20 0.41
GSK3A P49840 1/20 0.41
GSK3B P49841 1/20 0.41
NPSR1 Q6W5P4 3/20 0.40
ALDH1A1 P00352 2/20 0.40
BRAF P15056 1/20 0.39
TP53 P04637 2/20 0.38
TERT O14746 1/20 0.38
NSD2 O96028 1/20 0.38
KDM4E B2RXH2 2/20 0.38
MEN1 O00255 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Pazelliptine SCHEMBL1230570 0.99 KIT (0.71) KITPDGFRAFGFR3PAX8GAA
Pazelliptine SCHEMBL62441 0.99 KIT (0.73) KITPDGFRAFGFR3PAX8GAA
Pazelliptine SCHEMBL29376377 0.99 KIT (0.73) KITPDGFRAFGFR3PAX8GAA
SCHEMBL2311857 0.93 KIT (0.65) KITPDGFRAFGFR3GAANPSR1
SCHEMBL13498771 0.92 KIT (0.66) KITPDGFRAFGFR3PAX8GAA
SCHEMBL12387163 0.90 KIT (0.61) KITPDGFRAFGFR3GAANPSR1
SCHEMBL2308783 0.89 KIT (0.59) KITPDGFRAFGFR3GAANPSR1
SCHEMBL2308791 0.85 KIT (0.55) KITPDGFRAFGFR3GAANPSR1
SCHEMBL2311605 0.85 KIT (0.54) KITPDGFRAFGFR3GAANPSR1
SCHEMBL1065037 0.85 KIT (0.78) KITPDGFRAFGFR3PAX8GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3782649-B1 BIODEGRADABLE POLYETHYLENE GLYCOL BASED WATER-INSOLUBLE HYDROGELS ASCENDIS PHARMA AS (DK) 2025-05-14 EP disclosed
US-20230381323-A1 RELEASABLE CONJUGATES FISH & RICHARDSON PC 2023-11-30 US disclosed
US-11786599-B2 Releasable conjugates QUIAPEG PHARMACEUTICALS AB (SE) 2023-10-17 US disclosed
US-20230123784-A1 Biodegradable Polyethylene Glycol Based Water-Insoluble Hydrogels ASCENDIS PHARMA A/S (DK) 2023-04-20 US disclosed
US-20230065814-A1 CONJUGATES OF-ELECTRON-PAIR-DONATING HETEROAROMATIC NITROGEN-COMPRISING COMPOUNDS ASCENDIS PHARMA A/S (DK) 2023-03-02 US disclosed
US-11559482-B2 Biodegradable polyethylene glycol based water-insoluble hydrogels ASCENDIS PHARMA A/S (DE) 2023-01-24 US disclosed
US-20220305129-A1 CONJUGATES OF HETEROAROMATIC NITROGEN-COMPRISING COMPOUNDS ASCENDIS PHARMA A/S (DK) 2022-09-29 US disclosed
EP-4011396-A1 RELEASABLE CONJUGATES QuiaPEG Pharmaceuticals AB (SE) 2022-06-15 EP disclosed
EP-3986472-A1 CONJUGATES OF HETEROAROMATIC NITROGEN-COMPRISING COMPOUNDS Ascendis Pharma A/S (DK) 2022-04-27 EP disclosed
EP-3986477-A1 CONJUGATES OF pi-ELECTRON-PAIR-DONATING HETEROAROMATIC NITROGEN-COMPRISING COMPOUNDS Ascendis Pharma A/S (DK) 2022-04-27 EP disclosed
EP-2741778-A1 POLYMERIC HYPERBRANCHED CARRIER-LINKED PRODRUGS Ascendis Pharma A/S (DK) 2014-06-18 EP disclosed
EP-2741782-A1 PROTEIN CARRIER-LINKED PRODRUGS Ascendis Pharma A/S (DK) 2014-06-18 EP disclosed
US-20130053301-A1 DIPEPTIDE-BASED PRODRUG LINKERS FOR ALIPHATIC AMINE-CONTAINING DRUGS ASCENDIS PHARMA A/S (DK) 2013-02-28 US disclosed
WO-2013024048-A1 POLYMERIC HYPERBRANCHED CARRIER-LINKED PRODRUGS ASCENDIS PHARMA A/S (DK) 2013-02-21 WO disclosed
WO-2013024047-A1 HIGH-LOADING WATER-SOLUBLE CARRIER-LINKED PRODRUGS ASCENDIS PHARMA A/S (DK) 2013-02-21 WO disclosed
WO-2013024049-A1 PROTEIN CARRIER-LINKED PRODRUGS ASCENDIS PHARMA A/S (DK) 2013-02-21 WO disclosed
US-20120156259-A1 Biodegradable Polyethylene Glycol Based Water-Insoluble Hydrogels ASCENDIS PHARMA A/S (DK) 2012-06-21 US disclosed
EP-2459220-A1 BIODEGRADABLE POLYETHYLENE GLYCOL BASED WATER-INSOLUBLE HYDROGELS Ascendis Pharma A/S (DK) 2012-06-06 EP disclosed
WO-2011089216-A1 DIPEPTIDE-BASED PRODRUG LINKERS FOR ALIPHATIC AMINE-CONTAINING DRUGS ASCENDIS PHARMA AS (DK) 2011-07-28 WO disclosed
WO-2011012715-A1 BIODEGRADABLE POLYETHYLENE GLYCOL BASED WATER-INSOLUBLE HYDROGELS ASCENDIS PHARMA AS (DK) 2011-02-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120156259-A1 Biodegradable Polyethylene Glycol Based Water-Insoluble Hydrogels PLG, PHYKPL, PLOD3 KIT 1589/4885PDGFRA 2687/4885FGFR3 427/4885
US-20130053301-A1 DIPEPTIDE-BASED PRODRUG LINKERS FOR ALIPHATIC AMINE-CONTAINING DRUGS DNPEP, PEPD, DAO KIT 2203/4885PDGFRA 1772/4885FGFR3 1170/4885
US-20230123784-A1 Biodegradable Polyethylene Glycol Based Water-Insoluble Hydrogels PLG, PHYKPL, PLOD3 KIT 1589/4885PDGFRA 2687/4885FGFR3 427/4885
US-20220305129-A1 CONJUGATES OF HETEROAROMATIC NITROGEN-COMPRISING COMPOUNDS NQO1, ABCB1, NCL KIT 744/4885PDGFRA 1927/4885FGFR3 1634/4885
US-20230381323-A1 RELEASABLE CONJUGATES GUSB, ABCB11, UGT2B7 KIT 1226/4885PDGFRA 2590/4885FGFR3 3058/4885
US-20230065814-A1 CONJUGATES OF-ELECTRON-PAIR-DONATING HETEROAROMATIC NITROGEN-COMPRISING COMPOUNDS NQO1, NCL, ABCB1 KIT 1187/4885PDGFRA 2478/4885FGFR3 2581/4885
US-11559482-B2 Biodegradable polyethylene glycol based water-insoluble hydrogels PLG, PHYKPL, PLOD3 KIT 1589/4885PDGFRA 2687/4885FGFR3 427/4885
US-11786599-B2 Releasable conjugates GUSB, ABCB11, UGT2B7 KIT 1226/4885PDGFRA 2590/4885FGFR3 3058/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.